Insight

Nicola Gökbuget: Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL

Photo taken from Nicola Gökbuget/LinkedIn

Jan 18, 2024, 10:38

Nicola Gökbuget: Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL

Nicola Gökbuget, Head of Clinical Trial Center at Goethe University Hospital, posted on LinkedIn:

“The 65th Annual Meeting of the American Society of Hematology is now on month ago! Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL and to thank all contributors: 3 oral presentations and 2 posters.

This includes surprising results on potential systemic antileukemic effects of prophylactic CNS irradiation in B-precursor ALL and very promising results of the BOLD trial with dose reduced chemotherapy combined with immunotherapy in older patients with ALL.

1) CNS Irradiation in Adult De Novo B-Precursor ALL / LBL: Results of the Randomized GMALL Trial 08/2013 Indicate Potential Antileukemic Efficacy (Goekbuget et al; Blood 2023, 142 (Supp 1): 828.)

2) Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial (Goekbuget et al; Blood 2023, 142 (Supp 1): 964)

3) Molecular Subtypes in BCR::ABL1-Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events (Bastian et al; Blood 2023, 142 (Supp 1): 843.

4) Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lymphoblastic Leukemia (Bending et al; Blood 2023, 142 (Supp 1): 4354)

5) Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph- Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial (Fransecky et al; Blood 2023, 142 (Supp 1): 1502)

Further Details.”

Source: Nicola Gökbuget/LinkedIn